How do you decide which immunotherapy agent to utilize for 1st line in PD-L1 high (>50%) NSCLC?  

Are there specific clinical factors, efficacy, or treatment tolerability issues that lead you to favor one agent over another?

How do you compare or contrast data from IMPower110 vs KEYNOTE-024?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Kaiser Permanente
Would you also consider the biomarker for atezoliz...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
And in the real-life trenches experience, it also ...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice